Literature DB >> 30312238

Inflammation, Cerebral Vasospasm, and Brain Injury in Subarachnoid Hemorrhage-A Shifting Paradigm and a New Beginning.

Sherry Hsiang-Yi Chou1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 30312238      PMCID： PMC6195224          DOI： 10.1097/CCM.0000000000003373

Source DB:  PubMed          Journal:  Crit Care Med        ISSN： 0090-3493            Impact factor:   7.598


× No keyword cloud information.
  29 in total

1.  Outcomes and Costs of Patients Admitted to the ICU Due to Spontaneous Intracranial Hemorrhage.

Authors:  Shannon M Fernando; Peter M Reardon; Dar Dowlatshahi; Shane W English; Kednapa Thavorn; Peter Tanuseputro; Jeffrey J Perry; Erin Rosenberg; Eelco F Wijdicks; Daren K Heyland; Kwadwo Kyeremanteng
Journal:  Crit Care Med       Date:  2018-05       Impact factor: 7.598

2.  Cerebral infarction after subarachnoid hemorrhage contributes to poor outcome by vasospasm-dependent and -independent effects.

Authors:  Mervyn D I Vergouwen; Don Ilodigwe; R Loch Macdonald
Journal:  Stroke       Date:  2011-02-10       Impact factor: 7.914

Review 3.  Delayed cerebral ischaemia after subarachnoid haemorrhage: looking beyond vasospasm.

Authors:  M J Rowland; G Hadjipavlou; M Kelly; J Westbrook; K T S Pattinson
Journal:  Br J Anaesth       Date:  2012-09       Impact factor: 9.166

Review 4.  Inflammation in subarachnoid hemorrhage and delayed deterioration associated with vasospasm: a review.

Authors:  J Javier Provencio
Journal:  Acta Neurochir Suppl       Date:  2013

5.  High-mobility group box 1 protein in CSF of patients with subarachnoid hemorrhage.

Authors:  Takashi Nakahara; Ryosuke Tsuruta; Tadashi Kaneko; Susumu Yamashita; Motoki Fujita; Shunji Kasaoka; Teruto Hashiguchi; Michiyasu Suzuki; Ikuro Maruyama; Tsuyoshi Maekawa
Journal:  Neurocrit Care       Date:  2009-09-24       Impact factor: 3.210

6.  Time course of vasospasm in man.

Authors:  B Weir; M Grace; J Hansen; C Rothberg
Journal:  J Neurosurg       Date:  1978-02       Impact factor: 5.115

7.  A randomized trial of two doses of nicardipine in aneurysmal subarachnoid hemorrhage. A report of the Cooperative Aneurysm Study.

Authors:  E C Haley; N F Kassell; J C Torner; L L Truskowski; T P Germanson
Journal:  J Neurosurg       Date:  1994-05       Impact factor: 5.115

Review 8.  Monitoring biomarkers of cellular injury and death in acute brain injury.

Authors:  Sherry H-Y Chou; Claudia S Robertson
Journal:  Neurocrit Care       Date:  2014-12       Impact factor: 3.210

9.  Simvastatin in aneurysmal subarachnoid haemorrhage (STASH): a multicentre randomised phase 3 trial.

Authors:  Peter J Kirkpatrick; Carole L Turner; Christopher Smith; Peter J Hutchinson; Gordon D Murray
Journal:  Lancet Neurol       Date:  2014-05-15       Impact factor: 44.182

10.  Therapeutic targeting of HMGB1 during experimental sepsis modulates the inflammatory cytokine profile to one associated with improved clinical outcomes.

Authors:  Natalie E Stevens; Marianne J Chapman; Cara K Fraser; Tim R Kuchel; John D Hayball; Kerrilyn R Diener
Journal:  Sci Rep       Date:  2017-07-19       Impact factor: 4.379
View more
  3 in total

1.  CSF lipocalin-2 increases early in subarachnoid hemorrhage are associated with neuroinflammation and unfavorable outcome.

Authors:  Fang Yu; Aisha Saand; Changhong Xing; Jong Woo Lee; Liangge Hsu; Octavia P Palmer; Vanessa Jackson; Lu Tang; MingMing Ning; Rose Du; Patrick M Kochanek; Eng H Lo; Sherry H-Y Chou
Journal:  J Cereb Blood Flow Metab       Date:  2021-05-05       Impact factor: 6.200

2.  A Highly Predictive MicroRNA Panel for Determining Delayed Cerebral Vasospasm Risk Following Aneurysmal Subarachnoid Hemorrhage.

Authors:  Wang-Xia Wang; Joe E Springer; Kevin Xie; David W Fardo; Kevin W Hatton
Journal:  Front Mol Biosci       Date:  2021-05-14

3.  Targeting High Mobility Group Box 1 in Subarachnoid Hemorrhage: A Systematic Review.

Authors:  Sajjad Muhammad; Shafqat Rasul Chaudhry; Ulf Dietrich Kahlert; Martin Lehecka; Miikka Korja; Mika Niemelä; Daniel Hänggi
Journal:  Int J Mol Sci       Date:  2020-04-14       Impact factor: 5.923
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.